Eli Lilly (NYSE:LLY) just delivered one of the most impressive quarters in big pharma history, and the stock is responding.

The Investment Committee gives you their top stocks to watch for the second half.

Eli Lilly has made a six-year, $50 million commitment to UNICEF USA to support efforts to improve the prevention, detection ...

Eli-Lilly has launched India’s first disease-modifying Alzheimer’s drug, donenemab, under the brand name Lormalzi. Approved by the CDSCO in 2025, the treatment aims to slow cognitive decline in ...

The Indianapolis-based drugmaker will work to support UNICEF’s efforts to strengthen primary health care systems to prevent, ...

The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player ...

Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.

The S&P 500, which is a leading benchmark of the US stock market performance, has surged by around 8.7% since the beginning ...

The battle of weightloss-medicine keeps escalating, as new product has entered the market.

The launch of Eli Lilly’s Alzheimer’s therapy Lormalzi (donanemab) in India marks a significant shift in the treatment of the neurodegenerative disorder, with experts describing it as one of the first ...

Novo Nordisk and Biogen are underpriced and stand to gain from new indications for their blockbuster therapies.

Orforglipron offers an "effective approach" for sustaining weight loss, especially for those not wishing to remain on jabs, a ...